Molckovsky D, Boucher M
Issues Emerg Health Technol. 2004 Nov(62):1-4.
Ximelagatran (Exanta (R) is the first oral anticoagulant in a new class of drugs called direct thrombin inhibitors. Two studies suggest that ximelagatran is at least as effective as warfarin in preventing stroke in high risk patients with atrial fibrillation. Ximelagatran may also reduce the rate of major cardiovascular events after a myocardial infarction, compared to placebo. Ximelagatran does not require dose adjustments or routine blood monitoring. As with warfarin, bleeding risks increase with higher doses of ximelagatran. There is, however, no specific antidote to help manage bleeding. The safety of ximelagatran will not be fully known without further evaluation and surveillance for potential liver toxicity and drug interactions.
希美加群（Exanta（R））是一类名为直接凝血酶抑制剂的新型药物中的首个口服抗凝剂。两项研究表明，在预防高危房颤患者中风方面，希美加群至少与华法林一样有效。与安慰剂相比，希美加群还可能降低心肌梗死后主要心血管事件的发生率。希美加群不需要调整剂量或进行常规血液监测。与华法林一样，希美加群剂量越高，出血风险越大。然而，目前尚无特效解毒剂来处理出血情况。在对潜在肝毒性和药物相互作用进行进一步评估和监测之前，希美加群的安全性尚不完全清楚。
